Literature DB >> 15315354

The expression of interleukin-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris.

Jiawen Li1, Dongsheng Li, Zhijian Tan.   

Abstract

To investigate the role of Interleukin-17 (IL-17), Interferon-gamma (IFN-gamma), and macrophage inflammatory protein-3 alpha (MIP-3alpha) in the pathogenesis of psoriasis, reverse transcriptase-polymerase chain reaction (RT-PCR) was used to semi-quantitatively analyze the mRNA expression of IL-17, IFN-gamma, and MIP-3alpha in 31 psoriatic lesions and 16 normal skin tissues. The results showed that the mRNA of the three cytokines was present in all specimens. And the expression level of IL-17 mRNA in skin lesions was 1.1416 +/- 0.0591, which was significantly higher than that in normal controls (0.8788 +/- 0.0344, P<0.001). The expression levels of IFN-gamma mRNA were 1.1142 +/- 0.0561 and 0. 9050 +/- 0.0263, respectively, with significant difference (P<0.001). And the expression levels of MIP-3alpha mRNA in psoriatic lesions was 1.1397 +/- 0.0521, which was markedly higher than that in normal controls (0.8681 +/- 0.0308, P<0.001). These findings indicate that up-regulated expression of IL-17, IFN-gamma, and MIP-3alpha might be involved in the pathogenesis of psoriasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315354     DOI: 10.1007/bf02832018

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  8 in total

1.  The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients.

Authors:  L M Austin; M Ozawa; T Kikuchi; I B Walters; J G Krueger
Journal:  J Invest Dermatol       Date:  1999-11       Impact factor: 8.551

2.  Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines.

Authors:  M Chabaud; G Page; P Miossec
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

3.  Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis.

Authors:  B Homey; M C Dieu-Nosjean; A Wiesenborn; C Massacrier; J J Pin; E Oldham; D Catron; M E Buchanan; A Müller; R deWaal Malefyt; G Deng; R Orozco; T Ruzicka; P Lehmann; S Lebecque; C Caux; A Zlotnik
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

4.  Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes.

Authors:  C Albanesi; C Scarponi; A Cavani; M Federici; F Nasorri; G Girolomoni
Journal:  J Invest Dermatol       Date:  2000-07       Impact factor: 8.551

5.  Overexpression of monocyte-derived cytokines in active psoriasis: a relation to coexistent arthropathy.

Authors:  A Nishibu; G W Han; K Iwatsuki; T Matsui; M Inoue; H Akiba; R Kaneko; F Kaneko
Journal:  J Dermatol Sci       Date:  1999-09       Impact factor: 4.563

6.  Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes.

Authors:  M B Teunissen; C W Koomen; R de Waal Malefyt; E A Wierenga; J D Bos
Journal:  J Invest Dermatol       Date:  1998-10       Impact factor: 8.551

7.  T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines.

Authors:  F Fossiez; O Djossou; P Chomarat; L Flores-Romo; S Ait-Yahia; C Maat; J J Pin; P Garrone; E Garcia; S Saeland; D Blanchard; C Gaillard; B Das Mahapatra; E Rouvier; P Golstein; J Banchereau; S Lebecque
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

8.  Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors.

Authors:  M C Dieu-Nosjean; C Massacrier; B Homey; B Vanbervliet; J J Pin; A Vicari; S Lebecque; C Dezutter-Dambuyant; D Schmitt; A Zlotnik; C Caux
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

  8 in total
  13 in total

1.  IL-17 receptor and its functional significance in psoriatic arthritis.

Authors:  Siba P Raychaudhuri; Smriti K Raychaudhuri; Mark C Genovese
Journal:  Mol Cell Biochem       Date:  2011-09-06       Impact factor: 3.396

Review 2.  Regulation generation: the suppressive functions of human regulatory T cells.

Authors:  Wendy A Goodman; Kevin D Cooper; Thomas S McCormick
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

3.  Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma.

Authors:  Thorbjørn Krejsgaard; Ivan V Litvinov; Yang Wang; Lixin Xia; Andreas Willerslev-Olsen; Sergei B Koralov; Katharina L Kopp; Charlotte M Bonefeld; Mariusz A Wasik; Carsten Geisler; Anders Woetmann; Youwen Zhou; Denis Sasseville; Niels Odum
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

Review 4.  Regulation and function of proinflammatory TH17 cells.

Authors:  Gustavo J Martinez; Roza I Nurieva; Xuexian O Yang; Chen Dong
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

5.  Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial.

Authors:  M Caproni; E Antiga; L Melani; W Volpi; E Del Bianco; P Fabbri
Journal:  J Clin Immunol       Date:  2008-09-02       Impact factor: 8.317

Review 6.  IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa.

Authors:  J M Fletcher; B Moran; A Petrasca; C M Smith
Journal:  Clin Exp Immunol       Date:  2020-06-08       Impact factor: 4.330

Review 7.  From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited.

Authors:  Katia Boniface; Bianca Blom; Yong-Jun Liu; René de Waal Malefyt
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

8.  Increased IL17A, IFNG, and FOXP3 Transcripts in Moderate-Severe Psoriasis: A Major Influence Exerted by IL17A in Disease Severity.

Authors:  Priscilla Stela Santana de Oliveira; Michelly Cristiny Pereira; Simão Kalebe Silva de Paula; Emerson Vasconcelos Andrade Lima; Mariana Modesto de Andrade Lima; Rodrigo Gomes de Arruda; Wagner Luís Mendes de Oliveira; Ângela Luzia Branco Pinto Duarte; Ivan da Rocha Pitta; Moacyr Jesus Melo Barreto Rêgo; Maira Galdino da Rocha Pitta
Journal:  Mediators Inflamm       Date:  2016-11-30       Impact factor: 4.711

9.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.

Authors:  Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger
Journal:  J Exp Med       Date:  2007-11-26       Impact factor: 14.307

Review 10.  Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials.

Authors:  Benjamin Farahnik; Kourosh Beroukhim; Michael Abrouk; Mio Nakamura; Tian Hao Zhu; Rasnik Singh; Kristina Lee; Tina Bhutani; John Koo
Journal:  Dermatol Ther (Heidelb)       Date:  2016-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.